About
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Current Value
$15.831 Year Return
Current Value
$15.831 Year Return
Key Details
Market Cap
$1.64B
P/E Ratio
-3.6
1Y Stock Return
-43.30%
1Y Revenue Growth
-83.18%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include BEAM
Double maintains 4 strategies that include BEAM - Beam Therapeutics, Inc.
Growth at a Fair Price
High risk
$1,000
These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
195
Health Care Sector
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
Innovation Fund
High risk
$1,000
This strategy follows the ARKK fund (ticker ARKK) which was designed to seek long term capital from companies globally involved with, or that benefit from, disruptive innovation.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
33
Stock's related to BEAM
The stocks that are correlated to BEAM - Beam Therapeutics, Inc. are CRSP, NTLA, RXRX, DNLI, ABCL
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 72.46% | $2.80B | -49.80% | 0.00% | |
| 63.35% | $713.23M | -72.41% | 0.00% | |
| 62.70% | $1.93B | -44.90% | 0.00% | |
| 55.99% | $1.86B | -32.65% | 0.00% | |
| 55.77% | $622.79M | -52.50% | 0.00% | |
| 52.66% | $77.93M | -90.24% | 0.00% | |
| 50.62% | $73.01M | -82.71% | 0.00% | |
| 50.43% | $974.75M | -77.70% | 0.00% | |
| 50.20% | $1.18B | -15.60% | 0.00% | |
I IMNMImmunome, Inc. | 49.96% | $542.57M | -69.20% | 0.00% |
| 49.74% | $299.83M | -65.93% | 0.00% | |
| 49.24% | $1.66B | -53.81% | 0.00% | |
C CERSCerus Corp. | 49.04% | $239.67M | -31.75% | 0.00% |
| 48.91% | $1.10B | +171.43% | 0.00% | |
| 48.88% | $1.05B | +28.16% | 0.00% | |
| 48.43% | $1.69B | -43.02% | 3.27% | |
| 48.38% | $2.43B | -24.70% | 0.00% | |
| 48.29% | $843.00M | -60.46% | 0.00% | |
| 48.22% | $6.81B | -40.54% | 1.44% | |
D DIODDiodes, Inc. | 48.21% | $1.72B | -45.77% | 0.00% |
ETF's related to BEAM
The ETFs that are correlated to BEAM - Beam Therapeutics, Inc. are ARKG, CPRJ, GNOM, XBI, IWC
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 75.77% | $987.53M | 0.75% | |
| 75.16% | $48.65M | 0.69% | |
| 72.04% | $48.48M | 0.5% | |
X XBISPDR Biotech ETF | 64.23% | $5.06B | 0.35% |
| 60.87% | $809.63M | 0.6% | |
A ARKKARK Innovation ETF | 60.47% | $5.16B | 0.75% |
| 58.84% | $63.84B | 0.19% | |
| 58.77% | $11.24B | 0.07% | |
| 58.51% | $10.93B | 0.24% | |
| 58.50% | $5.70B | 0.45% | |
| 58.31% | $229.13M | 0.58% | |
| 57.34% | $320.39M | 0.79% | |
| 57.30% | $16.19B | 0.04% | |
| 56.89% | $11.04B | 0.24% | |
| 56.61% | $521.56M | 0.2% | |
| 56.57% | $2.38B | 0.39% | |
| 56.42% | $1.12B | 0.31% | |
| 56.14% | $842.66M | 0.6% | |
| 55.97% | $1.79B | 0.17% | |
| 55.52% | $169.45M | 0.79% | |
News
Finnhub
New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort Mean Decrease of 79% in Mutant Z-AAT...
Yahoo
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
Yahoo
Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug Administration. Marks, who played a crucial role in Operation Warp Speed and championed accelerated drug approvals, announced he was stepping down, citing irreconcilable differences with Health and Human Services Secretary Robert F. Kennedy Jr.
Yahoo
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.
Yahoo
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds